Allostery and Biased Agonism at Class B G Protein-Coupled Receptors
The DOI matches its Crossref record; 281 of the 281 references it cites were found in a registry or an index.
Abstract
Class B G protein-coupled receptors (GPCRs) respond to paracrine or endocrine peptide hormones involved in control of bone homeostasis, glucose regulation, satiety, and gastro-intestinal function, as well as pain transmission. These receptors are targets for existing drugs that treat osteoporosis, hypercalcaemia, Paget's disease, type II diabetes, and obesity and are being actively pursued as targets for numerous other diseases. Exploitation of class B receptors has been limited by difficulties with small molecule drug discovery and development and an under appreciation of factors governing optimal therapeutic efficacy. Recently, there has been increasing awareness of novel attributes of GPCR function that offer new opportunity for drug development. These include the presence of allosteric binding sites on the receptor that can be exploited as drug binding pockets and the ability of individual drugs to enrich subpopulations of receptor conformations to selectively control signaling, a phenomenon termed biased agonism. In this review, current knowledge of biased signaling and small molecule allostery within class B GPCRs is discussed, highlighting areas that have progressed significantly over the past decade, in addition to those that remain largely unexplored with respect to these phenomena.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As far as GIP is concerned, after binding its receptor on beta cells, GIP transduces its biological effects by increasing in cAMP and intracytoplasmic Ca2+ levels, in addition to the activation of PI3K, AKT, PKA, p38 MAP kinases and phospholipase A2 [41].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [41]
Citations
Cites
Items 201–281 of 281
Stress hormone secretion is altered by central administration of intermedin/adrenomedullin-2
Taylor, M. M., & Samson, W. K. (2005) · Brain Research · doi:10.1016/j.brainres.2005.03.034 · Cited by 50
A Role for Receptor Kinases in the Regulation of Class II G Protein-coupled Receptors
Shetzline, M. A., Premont, R. T., Walker, J. K. L., Vigna, S. R., & Caron, M. G. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.12.6756 · Cited by 49
VICKERY, B. H., Avnur, Z., Cheng, Y., Chiou, S., Leaffer, D., CAULFIELD, J. P., Ho, T., Krstenansky, J. L., & Kimmel, D. B. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650111216 · Cited by 48
Udawela, M., Christopoulos, G., Morfis, M. M., Christopoulos, A., Ye, S., Tilakaratne, N., & Sexton, P. M. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.024257 · Cited by 48
Self-citationPapadopoulou, N., Chen, J., Randeva, H. S., Levine, M. A., Hillhouse, E. W., & Grammatopoulos, D. K. (2004) · Molecular Endocrinology · doi:10.1210/me.2003-0365 · Cited by 47
Pattern of Intra-Family Hetero-Oligomerization Involving the G-Protein-Coupled Secretin Receptor
Harikumar, K. G., Morfis, M. M., Sexton, P. M., & Miller, L. J. (2008) · Journal of Molecular Neuroscience · doi:10.1007/s12031-008-9060-z · Cited by 47
Self-citationR. Drab, S. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666151223093841 · Cited by 47
Morris, L. C., Nance, K. D., Gentry, P. R., Days, E. L., Weaver, C. D., Niswender, C. M., Thompson, A. D., Jones, C. K., Locuson, C. W., Morrison, R. D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501375c · Cited by 47
Allosteric Modulators of Class B G-Protein-Coupled Receptors
Hoare, S. R. J. (2007) · Current Neuropharmacology · doi:10.2174/157015907781695928 · Cited by 46
Florea, V., Majid, S. S., Kanashiro‐Takeuchi, R. M., Cai, R., Block, N. L., Schally, A. V., Hare, J. M., & Rodrigues, C. O. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420375111 · Cited by 45
Harikumar, K. G., Happs, R. M., & Miller, L. J. (2008) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2008.07.008 · Cited by 45
Self-citationWietfeld, D., Heinrich, N., Furkert, J., Fechner, K., Beyermann, M., Bienert, M., & Berger, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405335200 · Cited by 45
Walker, C. S., Sundrum, T., & Hay, D. L. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12541 · Cited by 44
Hoang, H. N., Song, K., Hill, T. A., Derksen, D. R., Edmonds, D. J., Kok, W. M., Limberakis, C., Liras, S., Loria, P. M., Mascitti, V., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00166 · Cited by 44
Ramos-Álvarez, I., Mantey, S. A., Nakamura, T., Nuche‐Berenguer, B., Moreno, P., Moody, T. W., Maderdrut, J. L., Coy, D. H., & Jensen, R. T. (2015) · Peptides · doi:10.1016/j.peptides.2015.01.009 · Cited by 44
Kerr, B. D., Irwin, N., O'Harte, F. P. M., Bailey, C. J., Flatt, P. R., & Gault, V. A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.037 · Cited by 44
Dautzenberg, F. M., Gutknecht, E., der Linden, I. V., Olivares-Reyes, J. A., Dürrenberger, F., & Hauger, R. L. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.07.013 · Cited by 44
An overview of new GLP-1 receptor agonists for type 2 diabetes
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1123249 · Cited by 44
Recent progress in the development of small-molecule glucagon receptor antagonists
Sammons, M. F., & Lee, E. C. Y. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.07.092 · Cited by 43
Carter, P. H., Liu, R., Foster, W. R., Tamasi, J. A., Tebben, A. J., Favata, M. F., Staal, A., Cvijic, M. E., French, M. H., Dell, V., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605125104 · Cited by 43
Dalle, S., Smith, P. A., Blache, P., Le‐Nguyen, D., Brigand, L. L., Bergeron, F., Ashcroft, F. M., & BATAILLE, D. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.16.10869 · Cited by 43
Grace, C. R. R., Perrin, M. H., Gulyas, J., Rivier, J. E., Vale, W. W., & Riek, R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.121897 · Cited by 43
Glucagon and Cyclic AMP: Time to Turn the Page?
L. Rodgers, R. (2012) · Current Diabetes Reviews · doi:10.2174/157339912802083540 · Cited by 42
Koole, C., Wootten, D. L., Simms, J., Savage, E. E., Miller, L. J., Christopoulos, A., & Sexton, P. M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.309369 · Cited by 42
Self-citationHorwitz, M. J., Tedesco, M. B., Sereika, S. M., García-Ocaña, A., Bisello, A., Hollis, B. W., Gundberg, C. M., & Stewart, A. F. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1976-3 · Cited by 42
Koole, C., Savage, E. E., Christopoulos, A., Miller, L. J., Sexton, P. M., & Wootten, D. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1116 · Cited by 42
Self-citationWhitfield, J. F., Morley, P., Willick, G. E., Langille, R. M., Ross, V., MacLean, S., & Barbier, J. ‐. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.8.1246 · Cited by 41
Genomic Organization of the Rat Pituitary Adenylate Cyclase-activating Polypeptide Receptor Gene
Chatterjee, T. K., Liu, X., Davisson, R. L., & Fisher, R. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.18.12122 · Cited by 39
Identification and Characterization of a Small Molecule Antagonist of Human VPAC2 Receptor
Chu, A., Caldwell, J. S., & Chen, Y. A. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.060137 · Cited by 39
Inhibitory Mechanism of an Allosteric Antibody Targeting the Glucagon Receptor
Mukund, S., Shang, Y., Clarke, H. J., Madjidi, A., Corn, J. E., Kates, L., Kolumam, G. A., Chiang, V., Luis, E., Murray, J. M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.496984 · Cited by 38
Roed, S. N., Ørgaard, A., Jørgensen, R., & MEYTS, P. D. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00062 · Cited by 37
Wu, S. V., Yuan, P.-Q., Lai, J., Wong, K., Chen, M. C., Ohning, G. V., & Taché, Y. (2011) · Endocrinology · doi:10.1210/en.2010-0997 · Cited by 37
Dalle, S., Fontés, G., Lajoix, A.-D., LeBrigand, L., Gross, R., Ribes, G., Dufour, M., Barry, L., LeNguyen, D., & Bataille, D. (2002) · Diabetes · doi:10.2337/diabetes.51.2.406 · Cited by 37
Pepducins and Other Lipidated Peptides as Mechanistic Probes and Therapeutics
Zhang, P., Covic, L., & Kuliopulos, A. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2806-4_13 · Cited by 37
He, M., Guan, N., Gao, W.-W., Liu, Q., Wu, X.-Y., Ma, D.-W., Zhong, D.-F., Ge, G.-B., Li, C., Chen, X.-Y., et al. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.169 · Cited by 36
Dong, M., Xu, X., Ball, A. M., Makhoul, J. A., Lam, P. C. ‐., Pinon, D. I., Orry, A. J. W., Sexton, P. M., Abagyan, R. A., & Miller, L. J. (2012) · The FASEB Journal · doi:10.1096/fj.12-212399 · Cited by 36
Self-citationBianchi, E. N., & Ferrari, S. (2009) · Bone · doi:10.1016/j.bone.2009.06.020 · Cited by 36
Hay, D. L., Harris, P. W. R., Kowalczyk, R., Brimble, M. A., Rathbone, D. L., Barwell, J., Conner, A. C., & Poyner, D. R. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12464 · Cited by 35
Li, N., Lu, J., & Willars, G. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047936 · Cited by 35
Biological properties of adrenomedullin conjugated with polyethylene glycol
Kubo, K., Tokashiki, M., Kuwasako, K., Tamura, M., Tsuda, S., Kubo, S., Yoshizawa‐Kumagaye, K., Kato, J., & Kitamura, K. (2014) · Peptides · doi:10.1016/j.peptides.2014.05.005 · Cited by 34
Actions of the Small Molecule Ligands SW106 and AH-3960 on the Type-1 Parathyroid Hormone Receptor
Carter, P. H., Dean, T., Bhayana, B., Khatri, A., Rajur, R., & Gardella, T. J. (2015) · Molecular Endocrinology · doi:10.1210/me.2014-1129 · Cited by 34
Guo, X.-H. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1103214 · Cited by 33
Beyermann, M., Heinrich, N., Fechner, K., Furkert, J., Zhang, W., Kraetke, O., Bienert, M., & Berger, H. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707293 · Cited by 33
Ligand bias prevents class equality among beta-blockers
Thanawala, V. J., Forkuo, G. S., Stallaert, W., Leff, P., Bouvier, M., & Bond, R. A. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.03.002 · Cited by 32
Axelsen, L., Keung, W., Pedersen, H., Meier, E., Riber, D., Kjølbye, A., Petersen, J., Proctor, S., Holstein‐Rathlou, N., & Lopaschuk, G. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01714.x · Cited by 31
Hashimoto, H., Hyodo, S., Kawasaki, M., Shibata, M., Saito, T., Suzuki, H., Otsubo, H., Yokoyama, T., Fujihara, H., Higuchi, T., et al. (2007) · Peptides · doi:10.1016/j.peptides.2007.02.007 · Cited by 31
Chugunov, A. O., Simms, J., Poyner, D. R., Dehouck, Y., Rooman, M. J., Gilis, D., & Langer, I. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.063578 · Cited by 31
In vitro characterization of a human calcitonin receptor gene polymorphism
Wolfe, L. A., Fling, M. E., Xue, Z., Armour, S. L., Kerner, S. A., Way, J. M., Rimele, T., & Cox, R. F. (2003) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(02)00282-8 · Cited by 30
Eng, H. F., Sharma, R., McDonald, T. S., Edmonds, D. J., Fortin, J., Li, X., Stevens, B. D., Griffith, D. A., Limberakis, C., Nolte, W. M., et al. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.052183 · Cited by 30
Miller, L. J., Dong, M., & Harikumar, K. G. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01463.x · Cited by 28
Self-citationRodgers, R. L., MacLeod, K. M., & McNeill, J. H. (1981) · Circulation Research · doi:10.1161/01.res.49.1.216 · Cited by 28
Harney, J. A., & Rodgers, R. L. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90228.2008 · Cited by 28
Harikumar, K. G., Ball, A. M., Sexton, P. M., & Miller, L. J. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.06.001 · Cited by 28
Self-citationLaPierre, M. P., Abraham, M. A., Yue, J. T. Y., Filippi, B., & Lam, T. K. T. (2015) · EMBO Reports · doi:10.15252/embr.201540492 · Cited by 27
Dong, M., Koole, C., Wootten, D. L., Sexton, P. M., & Miller, L. J. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12293 · Cited by 25
Self-citationA thermodynamic approach to problems of drug antagonism I. The “Charniere theory”
Silva, M. R. E. (1969) · European Journal of Pharmacology · doi:10.1016/0014-2999(69)90188-5 · Cited by 24
Liu, Y., Yang, Y., Ward, R. J., An, S., Guo, X., Li, W., & Xu, T. (2015) · Biochemical Journal · doi:10.1042/bj20150358 · Cited by 24
Pellegrini, M., Bisello, A., Rosenblatt, M., Chorev, M., & Mierke, D. F. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970181o · Cited by 23
Dong, M., Cox, R. F., & Miller, L. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.011924 · Cited by 23
Self-citationKatayama, T., Furuya, M., Yamaichi, K., Konishi, K., Sugiura, N., Murafuji, H., Magota, K., Saito, M., Tanaka, S., & Oikawa, S. (2001) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(01)00125-8 · Cited by 23
β-Arrestin-biased signaling of PTH analogs of the type 1 parathyroid hormone receptor
van der Lee, M. M. C., Verkaar, F., Wat, J. W. Y., van Offenbeek, J., Timmerman, M., Voorneveld, L., van Lith, L. H. C. J., & Zaman, G. J. R. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.11.012 · Cited by 22
Irwin, N., Green, B. D., Gault, V. A., Cassidy, R. S., O'Harte, F. P. M., Harriott, P., & Flatt, P. R. (2005) · Peptides · doi:10.1016/j.peptides.2005.08.003 · Cited by 21
Koole, C., Wootten, D. L., Simms, J., Miller, L. J., Christopoulos, A., & Sexton, P. M. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.220913 · Cited by 21
Self-citationDifferential determinants for coupling of distinct G proteins with the class B secretin receptor
Garcia, G. L., Dong, M., & Miller, L. J. (2012) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00273.2011 · Cited by 21
Self-citationSonne, O., & Gliemann, J. (1977) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(77)90008-3 · Cited by 20
Langer, I., Gaspard, N., & Robberecht, P. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706816 · Cited by 20
Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis
Pοlyzos, S. A., Makras, P., Efstathiadou, Z. A., & Anastasilakis, A. D. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.973021 · Cited by 20
Growth hormone-releasing hormone and pituitary somatotrope proliferation.
La, F., & Kineman, R. D. (2002) · PubMed · Cited by 19
Modulation of β-Catenin Signaling by Glucagon Receptor Activation
Ke, J., Zhang, C., Harikumar, K. G., Diegel, C. R., Wang, L., Mowry, L. E., Miller, L. J., Williams, B. O., & Xu, H. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033676 · Cited by 18
Self-citationBoros, E. E., Cowan, D. J., Cox, R. F., Mebrahtu, M., Rabinowitz, M. H., Thompson, J. B., & Wolfe, L. A. (2005) · The Journal of Organic Chemistry · doi:10.1021/jo050370b · Cited by 18
Cheong, Y.-H., Kim, M.-K., Son, M.-H., & Kaang, B. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.12.004 · Cited by 17
Houslay, M. D., Wakelam, M. J. O., MURPHY, G. J., Gawler, D. J., & Pyne, N. J. (1987) · Biochemical Society Transactions · doi:10.1042/bst0150021 · Cited by 16
Employing novel animal models in the design of clinically efficacious GPCR ligands
Bradley, S. J., Riaz, S. A., & Tobin, A. B. (2014) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2013.12.002 · Cited by 12
ZP2307, a novel, cyclic PTH(1-17) analog that augments bone mass in ovariectomized rats
Neerup, T. S. R., Stahlhut, M., Petersen, J. S., Daugaard, J. R., Jensen, J. B., Peng, Z., Morko, J. P., & Thorkildsen, C. (2011) · Bone · doi:10.1016/j.bone.2011.02.019 · Cited by 12
Coy, D. H., Jiang, N.-Y., Fuselier, J. A., & Murphy, W. A. (2006) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb17480.x · Cited by 11
Conformational switches in the VPAC1receptor
Langer, I. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01616.x · Cited by 9
Markovic, D., & Grammatopoulos, D. K. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-652-8_21 · Cited by 9
Ago-allosteric modulators of human glucagon-like peptide 2 receptor
Yamazaki, K., Terauchi, H., Iida, D., Fukumoto, H., Suzuki, S., Kagaya, T., Aoki, M., Koyama, K., Seiki, T., Takase, K., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.08.026 · Cited by 8
Laville, M., Khalfallah, Y., Vidai, H., Beylot, M., Comte, B., & Riou, J. P. (1987) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(87)90023-2 · Cited by 5
Structure of a novel PTH‐related peptide hPTH′ and its interaction with the PTH receptor
Lin, K., Len, Y., Jao, F., Gao, H., You, Q., Lin, D., & Liu, J. (2012) · Journal of Peptide Science · doi:10.1002/psc.2412 · Cited by 2
Whitfield, J. F., Isaacs, R. J., Jouishomme, H., MacLean, S., Chakravarthy, B. R., Morley, P., Barisoni, D., Regalia, E., & Armato, U. (1996) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199601)166:1<1::aid-jcp1>3.0.co;2-t
Research works printed but not linked: 7
- 10.1124/pr.114.009464 · DOI
- 10.3109/10606820213681 · doi:10.3109/10606820213681 · Paper page
- Yamamoto Y., 2006, Cell Mol. Biol. (Noisy-le-grand), 52, 25
- 10.1124/mol.112.079319 · DOI
- Frohman L. A., 2002, Minerva Endocrinol., 27, 277
- 10.1210/mend.13.12.0391 · doi:10.1210/mend.13.12.0391 · Paper page
- 10.1210/jcem.85.5.6590 · doi:10.1210/jcem.85.5.6590 · Paper page
Cited by
Trends in GPCR drug discovery: new agents, targets and indications
Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schiöth, H. B., & Gloriam, D. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.178 · Cited by 2,627
The Current State of Peptide Drug Discovery: Back to the Future?
Henninot, A., Collins, J. C., & Nuss, J. M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00318 · Cited by 1,113
Mechanisms of signalling and biased agonism in G protein-coupled receptors
Wootten, D., Christopoulos, A., Marti-Solano, M., Babu, M. M., & Sexton, P. M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0049-3 · Cited by 724
Self-citationG protein-coupled receptors: structure- and function-based drug discovery
Yang, D., Zhou, Q., Labroska, V., Qin, S., Darbalaei, S., Wu, Y., Yuliantie, E., Xie, L., Tao, H., Cheng, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00435-w · Cited by 632
G protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery
Zhang, M., Chen, T., Lu, X., Lan, X., Chen, Z., & Lu, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01803-6 · Cited by 491
Metadata
- Authors
- Wootten, D., Miller, L. J., Koole, C., Christopoulos, A., & Sexton, P. M.
- Affiliations
- Monash University (AU)
- Mayo Clinic (US)
- Corresponding author
- Wootten, Denise
- Miller, Laurence J.
- Sexton, Patrick M.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-04-04
- Volume
- 117
- Issue
- 1
- Pages
- 111-138
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W2331593504
- Cited by
- 112
- References
- 280
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 7 · 2023: 9 · 2022: 18 · 2021: 10 · 2020: 12 · 2019: 12 · 2018: 17 · 2017: 10 · 2016: 3
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemical Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Health and Medical Research Council (1055134, 1061044, 1065410)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- class B G protein-coupled receptors, biased agonism, allosteric site, small molecule drug discovery, peptide hormones, osteoporosis, type 2 diabetes, obesity, drug development
- MeSH terms
- Allosteric Regulation, Structure-Activity Relationship, Dimerization, Receptors, G-Protein-Coupled
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.